<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439632</url>
  </required_header>
  <id_info>
    <org_study_id>Prulifloxacin aulut ZK-004</org_study_id>
    <nct_id>NCT02439632</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      prulifloxacin is not inferior to levofloxacin hydrochloride in treating acute uncomplicated&#xD;
      lower urinary tract infection in chinese&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of prulifloxacin film-coated tablet was meaured by the number of patient have been cured</measure>
    <time_frame>3 days</time_frame>
    <description>600mg single dose prolifloxacin is not inferior to Levoflxacin on low urine infection in Chinese</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of prulifloxacin film-coated tablet was measured by the number fo AE and SAE</measure>
    <time_frame>3 days and 28 days</time_frame>
    <description>The susceptibility of infecting strains to prulifloxacin;&#xD;
The rate of return to normal of WBC (white blood cell) in urine in treatment and control group&#xD;
The safety and tolerability of prulifloxacin in adult patients with acute lower urinary tract infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Acute Lower Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>prulifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.&#xD;
Placebo of levofloxacin hydrochloride tablet without active components.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.&#xD;
Placebo of prulifloxacin film-coated tablet, without active components.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prulifloxacin</intervention_name>
    <arm_group_label>prulifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin Placebo</intervention_name>
    <description>Placebo of prulifloxacin film-coated tablet without active components.</description>
    <arm_group_label>Levofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Placebo</intervention_name>
    <description>Placebo of levofloxacin hydrochloride tablet without active components.</description>
    <arm_group_label>prulifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 ~ 65 years old;&#xD;
&#xD;
          2. Presence at least two of the following clinical signs and symptoms of acute&#xD;
             uncomplicated lower urinary tract infection: dysuria, frequency, urgency and&#xD;
             suprapubic pain) with onset of symptoms ≤ 72 hours prior to study entry;&#xD;
&#xD;
          3. With pyuria: WBC &gt; 10/mm3 in unspun urine examined in a counting chamber or WBC &gt; 5/hp&#xD;
             [or the Upper laboratory Norm (UNL)] in the resuspended sediment of a centrifuged&#xD;
             aliquot of urine (or the UNL);&#xD;
&#xD;
          4. Patient is willing to participate in the study and gives the signature of informed&#xD;
             consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinical signs and symptoms suggestive of pyelonephritis or complicated&#xD;
             urinary tract infection (e.g., fever &gt; 37.5°C, chills, flank pain), or with factors&#xD;
             associated with complicated urinary tract infections such as presence of an indwelling&#xD;
             catheter or urologic abnormalities;&#xD;
&#xD;
          2. Women who are pregnant, nursing or plan to become pregnant in the near future (i.e.,&#xD;
             in three months). Women of childbearing potential (post-menopausal women must be&#xD;
             amenorrheic for at least 12 months to be considered of non-childbearing potential)&#xD;
             must have a negative serum pregnancy test at screening and must be willing to use an&#xD;
             acceptable method of contraception to avoid pregnancy throughout the study. Acceptable&#xD;
             methods of contraception include tubal ligation, oral contraceptive, barrier methods&#xD;
             (intra-uterine device, diaphragm, female condom, male condom);&#xD;
&#xD;
          3. Three or more episodes of acute uncomplicated UTI in the past 12 months;&#xD;
&#xD;
          4. Patients with overactive bladder;&#xD;
&#xD;
          5. Patients are hypersensitive to quinolones or with allergic constitution;&#xD;
&#xD;
          6. Administration of xanthines, fenbufen, antibiotics or antibacterials within the two&#xD;
             previous weeks;&#xD;
&#xD;
          7. Patients with severe condition which need combination with other antibacterial agents&#xD;
             or corticosteroids during the study;&#xD;
&#xD;
          8. Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of study drug (e.g., ulcerative disease, Inflammatory bowel&#xD;
             disease, lactose intolerance, or malabsorption syndrome)&#xD;
&#xD;
          9. Patients with severe liver or kidney disease, defined as serum ALT and AST ≥ 2.5 x ULN&#xD;
             and creatinine ≥ 1.5 x ULN;&#xD;
&#xD;
         10. Patients with severe heart disease or Q-T prolongation indicated by 12-lead ECG, or&#xD;
             arrhythmia or acute myocardial ischemia;&#xD;
&#xD;
         11. WBC &lt; 3.6 × 109/L or neutrophil &lt; 1.8 × 109/L, and/or platelets &lt; 90 × 109/L at&#xD;
             screening;&#xD;
&#xD;
         12. Patients with central nervous system disease or convulsion history, and/or with mental&#xD;
             status unable to coordinate;&#xD;
&#xD;
         13. Patients with malignant tumor or other severe background disease;&#xD;
&#xD;
         14. Patients with severe immunodeficiency;&#xD;
&#xD;
         15. Patients with a history of tendinopathy or who are currently having the disease,&#xD;
             including tendinitis and tendon rupture;&#xD;
&#xD;
         16. Patients treated with experimental drugs in the previous 4 weeks or currently;&#xD;
&#xD;
         17. Considered inappropriate for the study by investigators, including patients who are&#xD;
             unable or unwilling to show compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Medical Union Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

